Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

Journal of clinical pharmacy and therapeutics - 1 Feb 2015

Parakh S, Murphy C, Lau D, Cebon J S, Andrews M C

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: The management of metastatic melanoma has changed significantly in the past decade with the development of immunotherapies and targeted molecular therapies. Trials of targeted therapies have focused mainly on patients with the most common BRAF V600 mutations, namely V600E/K substitutions, with very little information available on the benefit of targeted therapies on less commonly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abdominal Neoplasms
Share to Imidazoles
Share to Intestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Molecular Targeted Therapy

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 25382067
DOI: 10.1111/jcpt.12229

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.PMID 25382067Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Biology and Treatment of BRAF Mutant Metastatic MelanomaSemantic proximity Read ↗

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanomas Without BRAF V600 Mutations.Semantic proximity Read ↗

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.Semantic proximity Read ↗

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.Semantic proximity Read ↗

BRAF L597K mutation: an opportunity to treat.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.